'Dear doctor...' - Evaluating the impact of risk communication efforts

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 4, 2003, Pages 291-293

  Seligman, Paul J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; NEW DRUG; TROGLITAZONE;

CLINICAL PRACTICE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HEALTH PRACTITIONER; HEART ARRHYTHMIA; HEARTBURN; HUMAN; INTERPERSONAL COMMUNICATION; LIVER TOXICITY; LONG QT SYNDROME; MEDICAL DECISION MAKING; MEDICAL INFORMATION; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK MANAGEMENT; TORSADE DES POINTES;

COMMUNICATION; DRUG MONITORING; DRUG THERAPY; HUMANS; PHYSICIAN'S ROLE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037780899     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.829     Document Type: Editorial

References (8)

1. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration Regulatory Action. JAMA 2000; 284: 3036-3039.
2. Weatherby LB, Nordstrom BL, Fife D, Walker AM. The impact of wording in 'Dear doctor' letters and in black box labels. Clin Pharmacol Ther 2002; 72: 735-742.
3. Wetherby LB, Walker AM, Fife D, Vervaet P, Klausner AM. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. Pharmacoepidemiol Drug Safe 2001; 10: 211-218.
4. Guo JJ, Curkendall S, Jones JK, Fife D, Goehring E, She D. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Safe 2003; 12: 295-301.
5. Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286: 831-833.
6. Uhl K, Honig P. Risk management of marketed drugs: FDA and the interface with the practice of medicine. Pharmacoepidemiol Drug Safe 2001; 10: 205-208.
7. Centers for Education and Research on Therapeutics (CERTs). Website http//www.certs.hhs.gov [13 November 2000].
8. Managing the Risks From Medical Product Use: Creating a Risk Management Framework. Report to the FDA Commissioner from the Task Force on Risk Management. US Department of Health and Human Services, Food and Administration, May 1999.